-
-
-
-
-
-
-
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filin
-
-
-
-
-
-
-
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
-
-
-
-
-
-
-
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
-
-
-
-
-
-
-
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
-
-
-
-
-
-
-
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
-
-
-
-
-
-
-
Takeda Pharmaceutical (TAK) Reports Q3 EPS of JPY 154
-
-
-
-
-
-
-
Centogene N.V. (CNTG) Extends Partnership With Takeda (TAK)
-
1,198,563 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

